IL-2Rβγ-signaling contributes to regulatory T cell maintenance and stability in daclizumab HYP-treated RRMS patients Huss DJ, Mehta DS, You X, Riester K, Sheridan J, Amaravadi L, Elkins JS, Fontenot JD ACTRIMS-ECTRIMS 2014. 09/12/2014. CommentRecommendBookmarkWatch